Visit Canadian Psoriasis Biosimilar Position Statement to read their recommendations.
These recommendations include:
- If a drug plan is considering non-medical switching,
- If a drug plan is considering tiering
- All drug plans implementing biosimilar policies should conduct robust post-implementation surveillance.